218 related articles for article (PubMed ID: 22348081)
1. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.
Arnold SA; Rivera LB; Carbon JG; Toombs JE; Chang CL; Bradshaw AD; Brekken RA
PLoS One; 2012; 7(2):e31384. PubMed ID: 22348081
[TBL] [Abstract][Full Text] [Related]
2. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC.
Arnold S; Mira E; Muneer S; Korpanty G; Beck AW; Holloway SE; Mañes S; Brekken RA
Exp Biol Med (Maywood); 2008 Jul; 233(7):860-73. PubMed ID: 18445772
[TBL] [Abstract][Full Text] [Related]
3. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.
Arnold SA; Rivera LB; Miller AF; Carbon JG; Dineen SP; Xie Y; Castrillon DH; Sage EH; Puolakkainen P; Bradshaw AD; Brekken RA
Dis Model Mech; 2010; 3(1-2):57-72. PubMed ID: 20007485
[TBL] [Abstract][Full Text] [Related]
4. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
5. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age.
Reed MJ; Bradshaw AD; Shaw M; Sadoun E; Han N; Ferara N; Funk S; Puolakkainen P; Sage EH
J Cell Physiol; 2005 Sep; 204(3):800-7. PubMed ID: 15795937
[TBL] [Abstract][Full Text] [Related]
6. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
Said N; Motamed K
Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
[TBL] [Abstract][Full Text] [Related]
7. Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Ikemoto MJ; Kobara M; Nakata T
Eur J Pharmacol; 2022 Jan; 914():174681. PubMed ID: 34871556
[TBL] [Abstract][Full Text] [Related]
8. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.
Brekken RA; Puolakkainen P; Graves DC; Workman G; Lubkin SR; Sage EH
J Clin Invest; 2003 Feb; 111(4):487-95. PubMed ID: 12588887
[TBL] [Abstract][Full Text] [Related]
9. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma.
Mantoni TS; Schendel RR; Rödel F; Niedobitek G; Al-Assar O; Masamune A; Brunner TB
Cancer Biol Ther; 2008 Nov; 7(11):1806-15. PubMed ID: 18787407
[TBL] [Abstract][Full Text] [Related]
10. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction.
Schellings MW; Vanhoutte D; Swinnen M; Cleutjens JP; Debets J; van Leeuwen RE; d'Hooge J; Van de Werf F; Carmeliet P; Pinto YM; Sage EH; Heymans S
J Exp Med; 2009 Jan; 206(1):113-23. PubMed ID: 19103879
[TBL] [Abstract][Full Text] [Related]
11. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
12. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery.
Seet LF; Su R; Barathi VA; Lee WS; Poh R; Heng YM; Manser E; Vithana EN; Aung T; Weaver M; Sage EH; Wong TT
PLoS One; 2010 Feb; 5(2):e9415. PubMed ID: 20195533
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of diabetic nephropathy in SPARC-null mice.
Taneda S; Pippin JW; Sage EH; Hudkins KL; Takeuchi Y; Couser WG; Alpers CE
J Am Soc Nephrol; 2003 Apr; 14(4):968-80. PubMed ID: 12660331
[TBL] [Abstract][Full Text] [Related]
14. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight.
Bradshaw AD; Graves DC; Motamed K; Sage EH
Proc Natl Acad Sci U S A; 2003 May; 100(10):6045-50. PubMed ID: 12721366
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis.
Sangaletti S; Di Carlo E; Gariboldi S; Miotti S; Cappetti B; Parenza M; Rumio C; Brekken RA; Chiodoni C; Colombo MP
Cancer Res; 2008 Nov; 68(21):9050-9. PubMed ID: 18974151
[TBL] [Abstract][Full Text] [Related]
16. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.
Socha MJ; Manhiani M; Said N; Imig JD; Motamed K
Am J Pathol; 2007 Oct; 171(4):1104-12. PubMed ID: 17717147
[TBL] [Abstract][Full Text] [Related]
17. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
[TBL] [Abstract][Full Text] [Related]
18. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials.
Puolakkainen P; Bradshaw AD; Kyriakides TR; Reed M; Brekken R; Wight T; Bornstein P; Ratner B; Sage EH
Am J Pathol; 2003 Feb; 162(2):627-35. PubMed ID: 12547720
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice.
Yan Q; Clark JI; Wight TN; Sage EH
J Cell Sci; 2002 Jul; 115(Pt 13):2747-56. PubMed ID: 12077365
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
